Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK pharmacists warned of swine flu vaccination counterfeits

This article was originally published in Scrip

Executive Summary

"Unscrupulous traders" are likely to begin selling Tamiflu (oseltamivir) and Relenza (zanamivir) counterfeits if the swine flu situation escalates, the Royal Pharmaceutical Society of Great Britain (RPSBG) has warned. The alert comes in a letter to pharmacists providing information on the swine flu outbreak.

You may also be interested in...



EMEA's PROTECT project accepted for funding

The Innovative Medicines Initiative Joint Undertaking (IMI JU) has agreed to fund the PROTECT project (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium).

J&J comes out on top in US reputation study

Johnson & Johnson has reclaimed the top spot in the 10th Annual Harris Interactive Quotient Study, marking it as having the best reputation of the 60 most visible companies in the US.

Anti-epileptic Zebinix receives EU approval

The European Commission has granted a marketing authorisation for the novel once-daily anti-epileptic Zebinix (eslicarbazepine acetate) as an adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation, Bial and Eisai announced today.

Topics

UsernamePublicRestriction

Register

PL032870

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel